MBOT
Price
$2.55
Change
+$0.02 (+0.79%)
Updated
Aug 1 closing price
Capitalization
18.57M
10 days until earnings call
NBIX
Price
$128.91
Change
+$0.68 (+0.53%)
Updated
Aug 1 closing price
Capitalization
13.72B
94 days until earnings call
Interact to see
Advertisement

MBOT vs NBIX

Header iconMBOT vs NBIX Comparison
Open Charts MBOT vs NBIXBanner chart's image
Microbot Medical
Price$2.55
Change+$0.02 (+0.79%)
Volume$1.52M
Capitalization18.57M
Neurocrine Biosciences
Price$128.91
Change+$0.68 (+0.53%)
Volume$1.4M
Capitalization13.72B
MBOT vs NBIX Comparison Chart in %
Loading...
MBOT
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
NBIX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
A.I.Advisor
published Highlights

Notable companies

The most notable companies in this group are Amgen (NASDAQ:AMGN), Gilead Sciences (NASDAQ:GILD), Regeneron Pharmaceuticals (NASDAQ:REGN), IQVIA Holdings (NYSE:IQV), Biogen (NASDAQ:BIIB), Illumina (NASDAQ:ILMN), Incyte Corp (NASDAQ:INCY), Exact Sciences Corp (NASDAQ:EXAS), Moderna (NASDAQ:MRNA), Exelixis (NASDAQ:EXEL).

Industry description

Few industries pique investor interest like the high-risk, high-reward biotechnology sector. It is not unusual for a biotech company’s stock to soar in value following the development of a successful product...even if it is just as likely that tens of millions of dollars in research will lead to nothing substantial. Biotech companies earn headlines for developing lifesaving and (potentially) massively lucrative treatments for illness, but the industry’s scope extends beyond healthcare to food and agriculture, industrial processing, and more. Any company producing technology that incorporates biological organisms falls within the sector. The search for the next big thing in biotech may come with risk, but investors have reason for optimism. Biotech products like DNA sequencing and gene therapy are experiencing increased demand and decreasing prices, while rising populations around the world mean demand for food and agricultural products resistant to environmental factors. Biotech’s biggest names include multinational corporations like Johnson & Johnson, Amgen, and Roche, who each sport market capitalizations in the hundreds of billions of dollars. With new government rules opening China as a market for new treatments, the biotech sector holds significant growth potential – and corresponding profitability for investors.

Market Cap

The average market capitalization across the biotechnology Theme is 7B. The market cap for tickers in the group ranges from 658 to 220.19B. TMO holds the highest valuation in this group at 220.19B. The lowest valued company is MTEM at 658.

High and low price notable news

The average weekly price growth across all stocks in the biotechnology Theme was 5%. For the same Theme, the average monthly price growth was 7%, and the average quarterly price growth was 20%. MRSN experienced the highest price growth at 2,039%, while ADAP experienced the biggest fall at -77%.

Volume

The average weekly volume growth across all stocks in the biotechnology Theme was -1%. For the same stocks of the Theme, the average monthly volume growth was 73% and the average quarterly volume growth was 201%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 60
P/E Growth Rating: 76
Price Growth Rating: 56
SMR Rating: 88
Profit Risk Rating: 90
Seasonality Score: -20 (-100 ... +100)

Market Cap

The average market capitalization across the group is 6.87B. The market cap for tickers in the group ranges from 18.57M to 13.72B. NBIX holds the highest valuation in this group at 13.72B. The lowest valued company is MBOT at 18.57M.

High and low price notable news

The average weekly price growth across all stocks in the group was -5%. For the same group, the average monthly price growth was 1%, and the average quarterly price growth was 12%. NBIX experienced the highest price growth at -2%, while MBOT experienced the biggest fall at -7%.

Volume

The average weekly volume growth across all stocks in the group was 84%. For the same stocks of the group, the average monthly volume growth was 162% and the average quarterly volume growth was 132%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 58
P/E Growth Rating: 75
Price Growth Rating: 43
SMR Rating: 78
Profit Risk Rating: 99
Seasonality Score: -62 (-100 ... +100)
VS
MBOT vs. NBIX commentary
Aug 02, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is MBOT is a Hold and NBIX is a StrongBuy.

Interact to see
Advertisement
COMPARISON
Comparison
Aug 02, 2025
Stock price -- (MBOT: $2.55 vs. NBIX: $128.91)
Brand notoriety: MBOT and NBIX are both not notable
MBOT represents the Medical Specialties, while NBIX is part of the Pharmaceuticals: Other industry
Current volume relative to the 65-day Moving Average: MBOT: 101% vs. NBIX: 151%
Market capitalization -- MBOT: $18.57M vs. NBIX: $13.72B
MBOT [@Medical Specialties] is valued at $18.57M. NBIX’s [@Pharmaceuticals: Other] market capitalization is $13.72B. The market cap for tickers in the [@Medical Specialties] industry ranges from $3.82T to $0. The market cap for tickers in the [@Pharmaceuticals: Other] industry ranges from $77.48B to $0. The average market capitalization across the [@Medical Specialties] industry is $8.67B. The average market capitalization across the [@Pharmaceuticals: Other] industry is $3.87B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

NBIX’s FA Score shows that 0 FA rating(s) are green whileMBOT’s FA Score has 0 green FA rating(s).

  • NBIX’s FA Score: 0 green, 5 red.
  • MBOT’s FA Score: 0 green, 5 red.
According to our system of comparison, NBIX is a better buy in the long-term than MBOT.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

MBOT’s TA Score shows that 6 TA indicator(s) are bullish while NBIX’s TA Score has 4 bullish TA indicator(s).

  • MBOT’s TA Score: 6 bullish, 4 bearish.
  • NBIX’s TA Score: 4 bullish, 5 bearish.
According to our system of comparison, MBOT is a better buy in the short-term than NBIX.

Price Growth

MBOT (@Medical Specialties) experienced а -6.93% price change this week, while NBIX (@Pharmaceuticals: Other) price change was -2.44% for the same time period.

The average weekly price growth across all stocks in the @Medical Specialties industry was -2.56%. For the same industry, the average monthly price growth was -2.26%, and the average quarterly price growth was -4.37%.

The average weekly price growth across all stocks in the @Pharmaceuticals: Other industry was -2.01%. For the same industry, the average monthly price growth was +5.21%, and the average quarterly price growth was +81.83%.

Reported Earning Dates

MBOT is expected to report earnings on Nov 07, 2025.

NBIX is expected to report earnings on Nov 04, 2025.

Industries' Descriptions

@Medical Specialties (-2.56% weekly)

Medical specialties are companies that make equipment used by the health care industry. Equipment manufactured and distributed by these companies include dialysis machines, blood analysis equipment, surgical equipment, dental instruments, and diagnostic tools, among other items. Large companies typically aim to produce and distribute high-quality products across a broad market spectrum. Smaller firms are more likely to specialize in a particular market segment. Due to the industry’s close association with medical treatments, they typically have low sensitivity to macroeconomic fluctuations. Within this industry, Abbott Laboratories, Medtronic Plc and Thermo Fisher Scientific Inc. are some of the companies with multi-billion market capitalizations in the U.S. stock markets.

@Pharmaceuticals: Other (-2.01% weekly)

Pharmaceuticals (Other) comprise companies that are involved in the discovery, development or manufacturing of therapeutic and preventative medicines. They often collaborate with or acquire other pharmaceutical/healthcare firms. Examples of companies in this segment include Bausch Health Companies Inc., Icon Plc and Perrigo Company Plc.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
NBIX($13.7B) has a higher market cap than MBOT($18.6M). MBOT YTD gains are higher at: 127.679 vs. NBIX (-5.560). NBIX has higher annual earnings (EBITDA): 358M vs. MBOT (-10.75M). NBIX has more cash in the bank: 1.03B vs. MBOT (8.15M). MBOT has less debt than NBIX: MBOT (245K) vs NBIX (428M). NBIX has higher revenues than MBOT: NBIX (1.89B) vs MBOT (0).
MBOTNBIXMBOT / NBIX
Capitalization18.6M13.7B0%
EBITDA-10.75M358M-3%
Gain YTD127.679-5.560-2,296%
P/E RatioN/A57.20-
Revenue01.89B-
Total Cash8.15M1.03B1%
Total Debt245K428M0%
FUNDAMENTALS RATINGS
NBIX vs MBOT: Fundamental Ratings
NBIX
MBOT
OUTLOOK RATING
1..100
1655
VALUATION
overvalued / fair valued / undervalued
1..100
70
Overvalued
46
Fair valued
PROFIT vs RISK RATING
1..100
98100
SMR RATING
1..100
6097
PRICE GROWTH RATING
1..100
4838
P/E GROWTH RATING
1..100
50100
SEASONALITY SCORE
1..100
n/an/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

MBOT's Valuation (46) in the Biotechnology industry is in the same range as NBIX (70). This means that MBOT’s stock grew similarly to NBIX’s over the last 12 months.

NBIX's Profit vs Risk Rating (98) in the Biotechnology industry is in the same range as MBOT (100). This means that NBIX’s stock grew similarly to MBOT’s over the last 12 months.

NBIX's SMR Rating (60) in the Biotechnology industry is somewhat better than the same rating for MBOT (97). This means that NBIX’s stock grew somewhat faster than MBOT’s over the last 12 months.

MBOT's Price Growth Rating (38) in the Biotechnology industry is in the same range as NBIX (48). This means that MBOT’s stock grew similarly to NBIX’s over the last 12 months.

NBIX's P/E Growth Rating (50) in the Biotechnology industry is somewhat better than the same rating for MBOT (100). This means that NBIX’s stock grew somewhat faster than MBOT’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
MBOTNBIX
RSI
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
68%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
82%
Bearish Trend 2 days ago
50%
Momentum
ODDS (%)
Bullish Trend 2 days ago
84%
Bearish Trend 2 days ago
55%
MACD
ODDS (%)
Bullish Trend 2 days ago
81%
Bearish Trend 2 days ago
61%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
80%
Bearish Trend 2 days ago
60%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
72%
Bullish Trend 2 days ago
73%
Advances
ODDS (%)
Bullish Trend 8 days ago
74%
Bullish Trend 3 days ago
72%
Declines
ODDS (%)
Bearish Trend 2 days ago
84%
Bearish Trend 12 days ago
61%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
84%
Bullish Trend 2 days ago
65%
Aroon
ODDS (%)
Bullish Trend 2 days ago
70%
Bullish Trend 2 days ago
67%
View a ticker or compare two or three
Interact to see
Advertisement
MBOT
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
NBIX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
YQQQ13.850.18
+1.33%
YieldMax Short N100 Option Inc Strgy ETF
PAB42.470.37
+0.89%
PGIM Active Aggregate Bond ETF
CMDY50.08-0.18
-0.37%
iShares Blmbrg Roll Sel Cmdty Strart ETF
AVIE59.51-0.27
-0.46%
Avantis Inflation Focused Equity ETF
IGRO76.08-0.70
-0.91%
iShares International Dividend Gr ETF

MBOT and Stocks

Correlation & Price change

A.I.dvisor indicates that over the last year, MBOT has been loosely correlated with POAI. These tickers have moved in lockstep 37% of the time. This A.I.-generated data suggests there is some statistical probability that if MBOT jumps, then POAI could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To MBOT
1D Price
Change %
MBOT100%
+0.79%
POAI - MBOT
37%
Loosely correlated
-3.42%
BNGO - MBOT
34%
Loosely correlated
-1.99%
CORBF - MBOT
33%
Loosely correlated
N/A
RCEL - MBOT
33%
Poorly correlated
-2.64%
OTCFF - MBOT
32%
Poorly correlated
-0.96%
More

NBIX and Stocks

Correlation & Price change

A.I.dvisor indicates that over the last year, NBIX has been loosely correlated with LFCR. These tickers have moved in lockstep 34% of the time. This A.I.-generated data suggests there is some statistical probability that if NBIX jumps, then LFCR could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To NBIX
1D Price
Change %
NBIX100%
+0.53%
LFCR - NBIX
34%
Loosely correlated
-0.14%
ELAN - NBIX
31%
Poorly correlated
+0.80%
EOLS - NBIX
31%
Poorly correlated
+2.12%
CGC - NBIX
30%
Poorly correlated
+1.94%
TLRY - NBIX
26%
Poorly correlated
-2.10%
More